Clinical Trial Update: Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase I study of Palomid 529, a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway, for advanced neovascular age-related macular degeneration has completed. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Palomid 529

Snippet

Sponsor: Paloma Pharmaceuticals, Inc. | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED